Fighting Blindness with 3D-NET "Drug Discovery & Development of Novel Eye Therapeutics"
Poster Feb 17, 2015
Pilar Ventosa-Andrés, Nils Ohnesorge, Yolanda Fernández, Yolanda Alvarez and Breandán Kennedy
Age-related macular degeneration (AMD), diabetic retinopathy (DR), and corneal inflammation are significant causes of irreversible blindness with increasing prevalence as the EU population ages and the “diabetes epidemic” expands. There is an unmet clinical need for more effective treatments to halt or reverse these diseases.
PAIN (vascular Permeability, Angiogenesis, Inflammation and Neurodegeneration) are pathological hallmarks of eye diseases that culminate in blindness. The discovery and development of safe and efficacious drugs modulating these processes will significantly improve the quality of life of patients with these diseases, will reduce the associated economic burden, and enhance pharmaceutical R&D in Europe.
The main researcher objectives of 3D-NET  are:
1. Discovery and development of drugs that target ocular pathologies, namely: retinal vascular permeability, unwanted blood vessel growth, inflammation and cell degeneration.
2. The 3D-NET consortium encompasses the capabilities and infrastructure required to test these drugs in relevant pre-clinical models of ocular disease
This project is funded through a Marie Curie Industry-Academia Pathways and Partnerships grant (IAPP) award from the EU Seventh Framework Programme (EU FP7 2013 - 612218/3D-NET). IAPP actions are based on the transfer of Knowledge and Technology between Industry and Academia.
Fc Effector Bioassays for Rapid and Quantitative Measurement of ADCC and ADCP Mechanisms of ActionPoster
Drug developers are rapidly adopting Fc effector function reporter-based bioassays to measure antibody Fc functions such as ADCC and ADCP activity during the development of therapeutic antibodies. Here we show application of a suite of FcgR Reporter Bioassays to elucidate and characterize antibody MOA.READ MORE
Analysis of the Effect of Aggregated β-Amyloid on Cellular Signaling Pathways Critical for Memory in Alzheimer’s DiseasePoster
Here we evaluate the ability to detect changes in phosphorylation levels of ERK and CREB following treatment with Aβ using the SH-SY5Y neuroblastoma cell line.READ MORE
Comments | 0 ADD COMMENT
Like what you just read? You can find similar content on the communities below.Biopharma Cell Science Diagnostics Drug Discovery Informatics & Automation Proteomics & Metabolomics
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for FreeLOGIN SUBSCRIBE FOR FREE